An open label, two stage, single period, single oral dose pharmacokinetic study of Remogliflozin etabonate tablet 100 mg and Remogliflozin etabonate tablet 250 mg of Glenmark pharmaceuticals ltd., India in normal, healthy, adult, human male subjects under fasting and/or fed condition
Latest Information Update: 10 Oct 2019
At a glance
- Drugs Remogliflozin etabonate (Primary)
- Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Glenmark Pharmaceuticals Ltd
- 04 Oct 2019 Results published in the Clinical Pharmacokinetics
- 08 Jan 2018 Status changed from not yet recruiting to completed.
- 02 Jan 2018 New trial record